EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors

Mark G Kirchhof, Vimal H Prajapati, Melinda Gooderham, Chih-Ho Hong, Charles W Lynde, Catherine Maari, Irina Turchin, Kim A Papp

Dermatology and Therapy · 2024-09 · 14 (9) · 2653-2668

DOI: 10.1007/s13555-024-01243-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology and Therapy, online erschienen am 08.08.2024. Verfasst von Mark G Kirchhof und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Division, Department of Medicine, University of Ottawa and The Ottawa Hospital, Ottawa, ON, Canada. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie Canada, Pfizer Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral Janus kinase inhibitors (JAKi), a class of advanced targeted systemic therapy, have demonstrated efficacy and safety in the treatment of moderate-to-severe atopic dermatitis (AD). Like other small molecules, oral JAKi have the potential for off-target effects including laboratory-related adverse events (AEs). Product labels for oral JAKi recommend an initial laboratory assessment and follow-up 4-12 weeks later to monitor for potential changes, based on evidence from clinical trials across therapeutic indications for oral JAKi, which may not reflect a population of moderate-to-severe AD patients typically seen in routine clinical practice. To address this gap, a panel of eight dermatologists with clinical and research experience with oral JAKi for the management of AD conducted a targeted review of the literature focused on key laboratory-related AEs associated with oral JAKi in the moderate-to-severe AD population. Based on the synthesis of evidence and informed opinion, a set of best practice statements related to fundamental standards of care and consensus recommendations on laboratory monitoring were suggested, and level of agreement was ascertained using a Likert scale from 0 to 100. There was a high level of agreement on three of the four suggested recommendations related to assessment and monitoring of key laboratory parameters and to dose reduction or switching in response to laboratory changes; there was a lower level of agreement related to the frequency of ongoing laboratory monitoring. Appropriate patient selection and laboratory assessment is an important strategy to mitigate the potential risks associated with oral JAKi when treating AD.

Schlagwörter

Stichwörter der Autor:innen

Atopic dermatitisJAK inhibitorsMonitoringSafetyTolerability

Autor:innen und Institutionen

  • Dermatology Division, Department of Medicine, University of Ottawa and The Ottawa Hospital, Ottawa, ON, Canada.
  • Probity Medical Research Inc., 135 Union St. E., Waterloo, ON, N2J 1C3, Canada.
  • Division of Dermatology, Department of Medicine, Section of Community Pediatrics, Department of Pediatrics; and Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada.
  • Skin Health and Wellness Centre, Calgary, AB, Canada.
  • Dermatology Research Institute, Calgary, AB, Canada.
  • Department of Dermatology, Queen's University, Kingston, ON, Canada.

Förderung

  • AbbVie Canada
  • Pfizer Canada

Zitieren

APA

Kirchhof, M. G., Prajapati, V. H., Gooderham, M., Hong, C. H., Lynde, C. W., Maari, C., Turchin, I., & Papp, K. A. (2024). Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors. Dermatology and Therapy, 14(9), 2653-2668. https://doi.org/10.1007/s13555-024-01243-8

Vancouver

Kirchhof MG, Prajapati VH, Gooderham M, Hong CH, Lynde CW, Maari C, et al. Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors. Dermatology and Therapy. 2024;14(9):2653-2668. doi:10.1007/s13555-024-01243-8

BibTeX
@article{Kirchhof2024,
  author = {Kirchhof, Mark G and Prajapati, Vimal H and Gooderham, Melinda and Hong, Chih-Ho and Lynde, Charles W and Maari, Catherine and Turchin, Irina and Papp, Kim A},
  title = {Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors},
  journal = {Dermatology and Therapy},
  year = {2024},
  volume = {14},
  number = {9},
  pages = {2653--2668},
  doi = {10.1007/s13555-024-01243-8}
}
Kostenlos starten →